rct
    2018
    High Quality

    S-Adenosyl methionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial

    Sarris J, Murphy J, Stough C, Mischoulon D, Bousman C, MacDonald P, Adams L, Nazareth S, Oliver G, Cribb L, Savage K, Menon R, Chamoli S, Berk M, Ng CH

    Published in Psychopharmacology

    Key Findings

    SAMe monotherapy did not significantly outperform placebo on depression rating scales over eight weeks.

    Conclusions

    A well-controlled trial found no monotherapy benefit for SAMe.

    Limitations

    Moderate sample; single dose regimen; high placebo response.

    Supplements Studied

    SAM-e
    Compound

    SAMe monotherapy did not significantly outperform placebo on depression rating scales over eight weeks.

    L-Methionine
    Amino Acid

    SAMe monotherapy did not significantly outperform placebo on depression rating scales over eight weeks.

    Outcomes Measured

    Depression Symptom Reduction

    SAMe monotherapy did not significantly outperform placebo over eight weeks.

    Related Health Concerns

    Depression

    Study Details

    Year:2018
    Sample Size:49
    Duration:8 weeks
    Quality Score:7/10

    Access Study

    View on DOIOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.